- Home
- MREO vs ALT Comparison
MREO vs ALT Comparison
Compare MREO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | ALT |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 573.8M |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MREO | ALT |
|---|---|---|
| Price | $0.30 | $2.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $1.97 | ★ $17.11 |
| AVG Volume (30 Days) | 1.5M | ★ 3.7M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $0.20 | $2.29 |
| 52 Week High | $2.37 | $6.44 |
Technical Indicators
Market Signals| Indicator | MREO | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 20.71 |
| Support Level | $0.26 | N/A |
| Resistance Level | $0.35 | $3.09 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 5.85 | 3.14 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.